-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $90 Price Target

Benzinga·12/19/2025 12:07:41
語音播報
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $90 price target.